Horizon scanning: US FDA approves regorafenib for advanced gastrointestinal stromal tumors

Source: US FDA Area: News The U.S. Food and Drug Administration (FDA) has approved regorafenib (Stivarga) for the treatment of patients with advanced gastrointestinal stromal tumours (GIST) that cannot be surgically removed and no longer respond to other FDA-approved treatments for this disease - imatinib and sunitinib.   The approval is based on the results of the GRID trial, previously reported on the NeLM in November 2012 - please see link below details.
Source: NeLM - News - Category: Drugs & Pharmacology Source Type: news